|Dr Clive Badman OBE
Clive Badman took up the role of Vice President, Pre-Competitive Activities in GSK R&D in October 2013 having previously been responsible for GSK’s supply chain for worldwide clinical trials and the scale up and transfers of products from trials into manufacturing. The same month, he also took on a role in the Business Engagement Group at Strathclyde University where he is a Visiting Professor and Chairman of CMAC (Continuous Manufacturing and Crystallisation).
In 2014, he took up the role of Project Director for REMEDIES, a project that brings together a broad mix of partners in a collaboration led by GSK and centred on Cambridge University’s Institute for Manufacturing. REMEDIES seeks to reimagine the entire medicines manufacturing and supply chain to make it fit for the challenges of 21st Century healthcare.
Clive joined Beecham Pharmaceuticals in 1978 and held positions of increasing responsibility in Development and Production in factories and central teams, before moving to GSK R&D in 2002. He has a BSc and PhD in Chemistry from Dundee University. He was awarded an OBE in 2012 for services to the Pharmaceutical Industry.
|Dr Jagjit Singh Srai
Jag Srai heads up the Centre for International manufacturing at the Institute for Manufacturing, part of the University of Cambridge’s engineering department. The Centre’s focus is on how to design the manufacturing supply chain of the future by adopting new technologies across the end to end supply chain.
Jag’s interest in supply chains stems from a career in international manufacturing operations, primarily in Unilever, where he was responsible for the design, analysis and operation of manufacturing supply chains, working in the UK and across Europe, and taking on technical, and supply chain director roles internationally. A technology transfer project with Cambridge University led to him undertaking a PhD in supply chain design before moving to the university 15 years ago.
John has spent most of his career as a consulting engineer working with pharmaceutical and life sciences organisations to build large-scale manufacturing facilities. His studies to complete an MBA in corporate innovation led him to pursue his interest in getting more involved in innovation. He has been able to bring his experience from the pharmaceutical industry together with his project management skills to guiding multi-partner CMAC collaborations. He is also working with Clive to bring the Medicines Manufacturing Innovation Centre (MMIC), an open innovation centre, to Scotland.
|Dr Liz Meehan
Liz has a degree in Polymer Science and Engineering, a PhD in Adhesion Science and is a material scientist with over 30 years’ industrial experience. She has worked in the Pharmaceutical Technology & Development function of AstraZeneca since 2003. She joined as an Associate Principal Scientist in Polymer Science focussed on developing a deeper understanding of structure-property relationships for polymeric excipients linked to excipient functionality in pharmaceutical dosage forms. In 2000 as an Associate Principal Scientist in Material Science she broadened her remit to include material properties of API, excipients and intermediates and their impact on drug product process and performance. In 2014, Liz progressed to Principal Scientist in Material Attributes and Product Performance and she currently has responsibility for the development of materials control strategies in drug product development to deliver robust pharmaceutical products and processes. She has worked on a variety of drug development projects involving a wide range of formulations and processes. She also has a responsibility to support materials science aspects of marketed pharmaceutical products throughout product life cycle management.
She is also a main board member of the International Pharmaceutical Excipients Council (IPEC) for Europe
Paul’s background was in engineering in the pharmaceutical industry moving later into licensing and health management roles. He is a mechanical engineer and MBA.
CrystecPharma started life as a very successful spin out from the University of Bradford that was sold to a US company, then brought back by Paul and one of its founders who relaunched it with many of its original team. Specialising in super-critical fluid technology in pharmaceutical crystal and particle engineering, it continues to work from Bradford with a wholly-owned subsidiary research company in Tianjin, China.
Tim previously worked in clinical packaging before becoming a project manager for the UK plastics industry working in London. He moved to CPI two years ago to work in the emerging field of printable electronics.
Charles is a process chemist who joined GSK’s Process Chemistry team 16 years ago after completing his undergraduate and PhD degrees. His work has been around developing new approaches and routes to manufacturing GSK API (active pharmaceutical ingredient) portfolio.
Charles has worked with both new products and existing GSK APIs and has joined the company’s continuous processing group looking at applying continuous processing technologies and seeing where and how continuous processing can add benefit to GSK’s manufacturing network.
Home » REMEDIES Team